PERSON – Page 9

FDA Approves Extended Dosing for Astellas’ Izervay, Intensifying Competition in Geographic Atrophy Treatment

2 months ago talkbio0Tagged Age related macular degeneration, Apellis, Approved, Astellas, dosing, Extension, eye treatment, Geographic Atrophy, IZERVAY, Syfovre, United States Food and Drug Administration

Izervay, Astellas, FDA approval, extended dosing, geographic atrophy, age-related macular degeneration, Syfovre, Apellis, eye treatment

Robert F. Kennedy Jr. Confirmed as HHS Secretary in Close Senate Vote

2 months ago talkbio0Tagged Administration occupational activities, CHARGE Syndrome, Confirmation, Health Policy, Healthy, RFK Jr., Secretary, Senate, Skepticism, Transplant Registry Unified Management Program, Vaccines

RFK Jr., HHS Secretary, Senate confirmation, Trump administration, vaccine skepticism, healthcare policy, Make America Healthy Again

Leadership Changes at Agios and Moderna: Board Resignation and New Marketing Chief

2 months ago talkbio0Tagged Agios, Board Resignation, Changing, Chief, David Schenkein, Drug Industry, Leadership, Mahery, marketing officer, Moderna

David Schenkein, Agios Pharmaceuticals, board resignation, Moderna, Amy Mahery, chief marketing officer, pharmaceutical industry, leadership changes

FDA Approves Extended Dosing for Astellas’ Izervay in Geographic Atrophy Treatment

2 months ago talkbio0Tagged Age related macular degeneration, Approved, Astellas, avacincaptad, dosing, Extension, Geographic Atrophy, IZERVAY, pegol, Pharma, United States Food and Drug Administration

Izervay, avacincaptad pegol, geographic atrophy, age-related macular degeneration, FDA approval, extended dosing, Astellas Pharma

SpringWorks Therapeutics Secures FDA Approval for Gomekli to Treat NF1-Related Tumors

2 months ago talkbio0Tagged Approved, disease treatment, Gomekli, Infrequent, Inhibitor, MEK, mirdametinib, Neurofibromatosis 1, Plexiform, Plexiform Neurofibroma, SpringWorks, United States Food and Drug Administration

SpringWorks Therapeutics, Gomekli, mirdametinib, FDA approval, neurofibromatosis type 1 (NF1), plexiform neurofibromas (PN), rare disease treatment, MEK inhibitor

FDA Approves SpringWorks’ Gomekli for Adult and Pediatric NF1-PN Patients

2 months ago talkbio0Tagged Approved, Gomekli, Inhibitor, MEK, mirdametinib, neurofibroma, Plexiform, SpringWorks, United States Food and Drug Administration

Gomekli, mirdametinib, neurofibromatosis type 1, plexiform neurofibromas, FDA approval, SpringWorks Therapeutics, MEK inhibitor

Novartis Acquires Anthos Therapeutics for $925M, Regaining Control of Promising Anticoagulant Abelacimab

3 months ago talkbio0Tagged abelacimab, Acquisition, Anthos, Anticoagulants, Atrial Fibrillation, cardiovascular pipeline, Cerebrovascular accident, Factor XI antibody, Novartis

Novartis, Anthos Therapeutics, acquisition, abelacimab, anticoagulant, Factor XI inhibitor, atrial fibrillation, stroke prevention, cardiovascular pipeline

Merck KGaA in Advanced Talks to Acquire SpringWorks Therapeutics, Bolstering Oncology Portfolio

3 months ago talkbio0Tagged Acquisition, Drug Industry, Gomekli, Merck KGaA, Neoplasms, Ogsiveo, SpringWorks

Merck KGaA, SpringWorks Therapeutics, acquisition, oncology, rare diseases, Ogsiveo, Gomekli, pharmaceutical industry

Personalized Cancer Vaccine Shows Promise in Preventing Recurrence of Advanced Kidney Cancer

3 months ago talkbio0Tagged cell renal cell carcinoma, Conventional (Clear Cell) Renal Cell Carcinoma, Immunotherapy, Malignant neoplasm of kidney, Neoantigen, personalized cancer, phase 1 trial

personalized cancer vaccine, kidney cancer, clear cell renal cell carcinoma (ccRCC), neoantigen, immunotherapy, cancer recurrence prevention, phase 1 trial

Eli Lilly’s Zepbound Surpasses $4.9 Billion in First Year Sales Despite Q4 Shortfall

3 months ago talkbio0Tagged Advice, earnings, Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Obesity, pharmaceutical revenue, Zepbound

Eli Lilly, Zepbound, obesity drug, Q4 2024 earnings, pharmaceutical revenue, GLP-1 medications, Mounjaro, 2025 guidance